Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PanCan and Precision Promise fails FibroGen

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Jul 31, 2024 10:55am

193 Views

Post# 36156191

PanCan and Precision Promise fails FibroGen

July 31, 2024 - Pamrevlumab arm of the Precision Promise^SM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Cancer Action Network (PanCAN), did not meet the primary endpoint of overall survival as determined by the protocol pre-specified Bayesian statistical analysis.

https://www.biospace.com/fibrogen-announces-topline-results-from-two-late-stage-pamrevlumab-pancreatic-cancer-studies-and-provides-corporate-update

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing